openPR Logo
Press release

The Drug-Resistant Tuberculosis Treatment Market To Show Impeccable Growth In The Forecast Period

06-23-2022 12:00 PM CET | Health & Medicine

Press release from: Persistence Market Research

The Drug-Resistant Tuberculosis Treatment Market To Show

Environmental sciences are being used for creating awareness regarding hygiene and robust health. With adoption of HER/EMR solutions on the rise, the risk of insufficient protection/loopholes can't be ruled out. There is every likelihood of company employees and patients alike getting targeted through sophisticated phishing attacks and social engineering. As such, cybersecurity should be in place, much before AI-organized system is incorporated. The drug-resistant tuberculosis treatment market would go this way in the next 10 years.

According to the latest research by Persistence Market Research, the Drug-Resistant Tuberculosis Treatment market is set to witness a growth of 5% during 2021-2031. Demand for Drug-Resistant Tuberculosis Treatment expects to witness steady recovery in the short-term, with an optimistic growth outlook in the long run. The growing advancement for the Drug-Resistant Tuberculosis Treatment market industry will offer lucrative opportunities in near future.

The WHO has described the global effects of multidrug-resistant tuberculosis (MDR TB) as a "public health crisis". In 2013, an estimated 480,000 new cases and 210,000 deaths were caused by MDR TB which is defined by resistance to isoniazid and rifampin, the 2 most effective anti-TB drugs.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32634

In addition, approximately 9% of MDR TB cases are believed to be extensively drug-resistant (XDR TB), which implies additional resistance to any fluoroquinolone and at least 1 injectable second-line drug. Treatment of MDR and XDR TB requires prolonged therapy with toxic, poorly tolerated medications, and for patients in developing countries, access to active drugs may be limited.

Drug-resistant TB is the largest single source of antimicrobial resistance in the world. According to WHO, approximately half a million people worldwide are diagnosed with multi-drug-resistant TB each year, and about 8.5% of those people have XDR TB.

Common TB treatments don't work on XDR TB, so people with this extreme form of the disease need to take a combination of around eight drugs for more than a year. This growing number of drug-resistant tuberculosis will act as a driver for drug-resistant tuberculosis treatment market growth in the forecasted period.

There has been continuous research going on in the drug-resistant tuberculosis treatment field. FDA is actively involved in the approval of the related drugs. For instance, in Aug 2019, FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis. This continuous R&D will attract the market in the forecasted period.

Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32634

North America held the majority of the revenue share of the global market in 2020. There has been a significant increase in the number of cases of MDR-TB in the United States. Although cases of MDR-TB have been reported from many areas of the country, the majority of the cases are concentrated in large urban areas.

MDR-TB is difficult and expensive to treat. CDC has developed a National Action Plan to Combat Multidrug-Resistant Tuberculosis. The U.S. has large support from government and insurance providers to facilitate the healthcare system. As the cell therapy treatment are expensive the favorable healthcare system of the region will promote the growth of the market in the forecasted period. Besides being a developed nation clinical trials are going on in the region facilitating the adoption of cell therapy.

Asia is the second-largest market for drug-resistant tuberculosis treatment. According to WHO, it is estimated that 171,000 Rifampicin-resistant (RR) and multi-drug-resistant TB (MDR-TB) cases accounting for more than 35% of global burden appeared in the region in 2019, of which around 70,000 were started on second-line treatment in the same year.

Six out of the 30 high TB (and MDR-TB) burden countries are in the region are Bangladesh, the Democratic People's Republic of Korea, India, Indonesia, Myanmar, and Thailand. Central Asia accounts for 85% of the tuberculosis incidence and more than 90% of drug-resistant tuberculosis cases emerging in the region. This huge prevalence of MDR and XDR in the region will give rise to a drug-resistant tuberculosis treatment market in the forecasted period.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/32634

Some of the key players of Drug-Resistant Tuberculosis Treatment include,

Sanofi
Novartis AG
Endo International plc
CMP Pharma
STI Pharma LLC
Akorn Incorporated
Lupin
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/drug-resistant-tuberculosis-treatment-market.asp

Key Segments

By Drug Class

Amoxicillin/Clavulanate
Bedaquiline
Carbapenems with Clavulanic Acid
Clofazimine
Cycloserine
Delamanid
Ethambutol
Ethionamide and Prothionamide
Fluoroquinolones
Levofloxacin
Moxifloxacin
Ciprofloxacin
Ofloxacin
Linezolid
Macrolides
Azithromycin
Clarithromycin
p-Aminosalicylic Acid
Pyrazinamide

By Disease Type

Multidrug-Resistant TB (MDR TB)
Extensively Drug-resistant TB (XDR TB)

By Treatment Type

First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
Others

By Distribution channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others

Related Reports:

Rosacea Therapeutics Market - https://www.persistencemarketresearch.com/market-research/rosacea-treatment-market.asp

Pressure Relief Devices Market - https://www.persistencemarketresearch.com/market-research/pressure-relief-devices-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Drug-Resistant Tuberculosis Treatment Market To Show Impeccable Growth In The Forecast Period here

News-ID: 2660511 • Views: 190

More Releases from Persistence Market Research

Growing End-use Adoption to Fuel Sales Motorcycle Accessories Market During the …
The Motorcycle Accessories Market is expected to grow manifold in the upcoming period. With technological advancements like ML and AI being incorporated in abundance, the healthcare vertical is likely to reach the top pedestal in the years to come. There are Bluetooth-operated health monitors, which let doctors receive precise information, that too, from time to time. Improved economic outlook across the globe resulted into substantial increase in purchasing power of consumers
Motorcycle Market is anticipated to expand at a CAGR of around 4% over the forec …
The global motorcycle market is anticipated to expand at a CAGR of around 4% over the forecast period of 2021-2031, with demand for electric motorcycles to rise faster than previous years. The market is on course to top a valuation of US$ 181 Bn by the end of 2031. Increasing consumer preference for electric and hybrid motorcycles is anticipated to be a major factor driving global market expansion. Demand for affordable
Electric Cargo Bike Market Emerging Trends, with top Key Manufacturers
The global electric cargo bike market is expected to surge at a CAGR of 11.4% and top a valuation of US$ 1.1 Bn by 2031. The electric cargo bike industry is predicted to develop as customer preferences for electric bikes rise and new technological advances emerge. This report provides in depth study of "Electric Cargo Bike Market" using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Electric
Bicycle Accessories Market - industry analysis, size, share, growth, trends and …
Report Overview The global bicycle accessories market is estimated to expand at a healthy CAGR of close to 7% over the forecast period of 2021-2031. This report provides in depth study of "Bicycle Accessories Market" using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Bicycle Accessories Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning